OBJECTIVE: To compare the efficacy and safety of linezolid and vancomycin in the treatment of neonatal Gram-positive coccal pneumonia. METHODS: Totally 48 children with confirmed or suspected Gram-positive coccal pneumonia admitted into Guangxi Zhuang Autonomous Region National Hospital from Oct. 2016 to Mar. 2019 were extracted to be divided into linezolid group and vancomycin group via different treatment regimen

with 24 cases in each group. The clinical efficacy

the status of pathogen culture

the level of experimental indicators and adverse drug reactions of two groups were compared. RESULTS: The total effective rates of the linezolid group and vancomycin group were 87. 5%（ 21/24） and 83. 3%（ 20/24）

respectively

with no significant difference（ P > 0. 05）. The positive rates of pathogenic culture in the linezolid group and vancomycin group were 37. 5%（ 9/24） and 54. 2%（ 13/24）

respectively. After treatment

Gram-positive cocci were negative in both groups. Before and after treatment

there were no statistically significant differences in the absolute values of neutrophils

erythrocyte count

platelet count

total bilirubin

alanine aminotransferase and serum creatinine levels of two groups（ P>0. 05）. One child in the linezolid group had decreased platelet count

while no adverse drug reactions were observed in the vancomycin group.CONCLUSIONS: The efficacy of linezolid and vancomycin in the treatment of neonatal gram-positive coccal pneumonia is similar. Decreased platelet count was observed in individual cases in the linezolid group

which should be monitored regularly during medication.